Voyageur Pharmaceuticals Ltd.
FRC CoverageVoyageur Pharmaceuticals Ltd.
FRC CoverageYour view on VM.V
Overview
What the company does, where it operates, and who runs it.
*Voyageur Pharmaceuticals Ltd. has paid FRC a fee for research coverage and distribution of reports.
About Voyageur Pharmaceuticals Ltd.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Brent Willis Bsc.Eng
- Headquarters
- 339–50th Avenue SE, Calgary, AB, CA
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Brent Willis Bsc.Eng
- Headquarters
- 339–50th Avenue SE, Calgary, AB, CA
Voyageur Pharmaceuticals Ltd. focuses on the development of active pharmaceutical ingredients minerals. The company intends to develop barium and iodine radiocontrast products and bromine based pharmaceutical products.
It holds 100% interest in three barium sulfate deposits, including two properties suitable in grade for the pharmaceutical barite marketplace located in British Columbia, Canada; and interests in a high-grade iodine, lithium, and bromine brine project in Utah, the United States.
The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. is headquartered in Calgary, Canada.
Research Reports
FRC analyst coverage and recommendations.
Past Reports
Historical coverage archive.
Analyst Notes
Ongoing commentary and updates from FRC analysts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Voyageur Pharmaceuticals Ltd., and the rating behind it. VM.V last traded at C$0.13; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Voyageur Pharmaceuticals Ltd.. Starting points for Voyageur Pharmaceuticals Ltd.: EPS -C$0.02, beta 0.93 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Voyageur Pharmaceuticals Ltd.. Voyageur Pharmaceuticals Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Voyageur Pharmaceuticals Ltd.. Trailing twelve-month EPS for Voyageur Pharmaceuticals Ltd. stands at -C$0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Voyageur Pharmaceuticals Ltd.. Voyageur Pharmaceuticals Ltd. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Voyageur Pharmaceuticals Ltd. valued side by side against its closest peers. Voyageur Pharmaceuticals Ltd. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Voyageur Pharmaceuticals Ltd., and how their positions are changing. At a C$23.1M market value, institutional positions materially move Voyageur Pharmaceuticals Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Voyageur Pharmaceuticals Ltd. executives and directors. Shares of Voyageur Pharmaceuticals Ltd. have traded between C$0.0020 and C$0.25 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Voyageur Pharmaceuticals Ltd.. Voyageur Pharmaceuticals Ltd. is a C$23.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Voyageur Pharmaceuticals Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Voyageur Pharmaceuticals Ltd.. Coverage tracks Voyageur Pharmaceuticals Ltd. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.